Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000043

Director sold 105,000 shares at an average $58.97 ($6,191,366)

  • Director acquired 62,260 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Dambkowski Carl · Director

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-05-21 Exercise or conversion : show line 1 in the form 10b5-1 +38,689 $6.84 $264,633 155,172 D
2026-05-21 Exercise or conversion : show line 2 in the form 10b5-1 +11,904 $7.80 $92,851 167,076 D
2026-05-21 Exercise or conversion : show line 3 in the form 10b5-1 +11,667 $11.77 $137,321 178,743 D
2026-05-21 Sale : show line 4 in the form 10b5-1 −38,318 $58.43 $2,238,794 140,425 D
2026-05-21 Sale : show line 5 in the form 10b5-1 −53,447 $59.10 $3,158,910 86,978 D
2026-05-21 Sale : show line 6 in the form 10b5-1 −13,235 $59.97 $793,662 73,743 D
Open-market sales · 105,000 sh · avg $58.97 · $6,191,366

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2026-05-21 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (right to buy) −38,689 32,737 D
2026-05-21 Exercise or conversion : show line 8 in the form 10b5-1 Warrant (right to buy) −11,904 10,952 D
2026-05-21 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) −11,667 5,833 D
Loading xslF345X06/form4.xml…